Skip to content
lifestyle.trondstidkontroll.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
OPKO Health, Inc.
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
October 28, 2026
OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
October 27, 2026
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 8, 2026
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
August 13, 2026
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
July 27, 2026
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
July 23, 2026
Preclinical Data for OPKO Biologics’ OPK8801001 in Acromegaly Presented at ENDO 2026
June 15, 2026
OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
May 20, 2026
OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26
February 12, 2026